This site is intended for health professionals only

Shire builds competitive position of its HGT business

teaser

Shire plc, theglobal specialty biopharmaceutical company, announces today that it hasentered into a research-based collaboration with Santaris Pharma, aleading player in RNA-based therapeutics, to develop its proprietaryLocked Nucleic Acid (LNA) technology in a range of rare diseases,thereby enabling Shire to build on its already strong competitiveposition for its Human Genetic Therapies (HGT) business. LNA technologyhas the benefit of a very quick validated target to proof of conceptturnaround, thereby increasing the speed and lowering the cost ofdevelopment.

Currently, Shire HGT has a unique and successfulplatform producing human cell derived enzyme replacement therapies(ERTs) for a wide range of rare human genetic disorders.

Article continues below this sponsored advert
Advertisement

SylvieGrégoire, President of Shire HGT, comments, “With this novel platformtechnology Shire has the potential to move into a wider range ofgenetic orphan diseases. We will look to develop treatments for peoplewith a variety of rare life-altering and life-threatening conditionsthat to date, could not be effectively addressed by enzyme replacementtherapy.”

As part of the joint research project SantarisPharma will design, develop and deliver pre-clinical LNAoligonucleotides specific for the selected Shire targets, and Shirewill have the right to further develop and commercialize thesecandidate compounds on a worldwide basis.

Shire






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x